💊FDA Proposes Easing Access to 12 Unproven Peptide Drugs

FDA's move could open the floodgates for unproven peptide drugs

The FDA is proposing a new policy that would ease access to 12 unproven peptide drugs, potentially bypassing years of regulatory hurdles. This move could have significant implications for patient safety and the pharmaceutical industry. The proposed policy would give the FDA 'enforcement discretion' on certain peptide drugs, allowing the agency to choose not to enforce current restrictions. The FDA is currently re-reviewing these drugs, which were previously stricken from a list of drugs that can be made by specialty pharmacies due to safety and efficacy concerns. The FDA advisory panel has recommended adding six of the first seven peptides back to the list, despite FDA staff scientists maintaining that the drugs still lack data on safety and efficacy. The Center for Science in the Public Interest is urging the FDA to disregard the panel's recommendations. This policy could have significant implications for patients seeking unproven treatments and the pharmaceutical industry's regulatory landscape.